Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.

[1]  S. McGuire.  World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. , 2016, Advances in nutrition.

[2]  K. Attwood,et al.  Multidisciplinary Cancer Conferences for Gastrointestinal Malignancies Result in Measureable Treatment Changes: A Prospective Study of 149 Consecutive Patients , 2015, Annals of Surgical Oncology.

[3]  J. Borrás,et al.  Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. , 2015, Health policy.

[4]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer , 2015, International Journal of Clinical Oncology.

[5]  C. Boni,et al.  Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. , 2014, The New England journal of medicine.

[6]  E. Van Cutsem,et al.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[8]  Jianming Xu,et al.  Timing of Hepatectomy for Resectable Synchronous Colorectal Liver Metastases: For Whom Simultaneous Resection Is More Suitable - A Meta-Analysis , 2014, PloS one.

[9]  S. Jegatheeswaran,et al.  Management of colorectal cancer presenting with synchronous liver metastases , 2014, Nature Reviews Clinical Oncology.

[10]  E. Vibert,et al.  A proposed new method for assessing the pathological response to chemotherapy in resected colorectal liver metastases , 2014, British Journal of Cancer.

[11]  R. Golfieri,et al.  Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study , 2014, British Journal of Cancer.

[12]  R. Schilsky,et al.  CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Haglind,et al.  Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II) , 2014, The British journal of surgery.

[14]  G. Folprecht,et al.  Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. , 2014, European journal of cancer.

[15]  N. Sevdalis,et al.  Decision-making in Colorectal Cancer Tumor Board meetings: Results of a prospective observational assessment , 2014, Surgical Endoscopy.

[16]  R. Laugier,et al.  Place of colorectal stents in therapeutic management of malignant large bowel obstructions , 2014, Endoscopy.

[17]  M. Haider,et al.  Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. , 2014, JAMA.

[18]  K. Nastos,et al.  Systematic review of surgical management of synchronous colorectal liver metastases , 2014, The British journal of surgery.

[19]  D. Sahani,et al.  Current Status of Imaging and Emerging Techniques to Evaluate Liver Metastases From Colorectal Carcinoma , 2014, Annals of surgery.

[20]  W. Lau,et al.  Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a new strategy to increase resectability in liver surgery. , 2014, International journal of surgery.

[21]  Z. Hamady,et al.  One-Millimeter Cancer-Free Margin Is Curative for Colorectal Liver Metastases: A Propensity Score Case-Match Approach , 2014, Annals of surgery.

[22]  T. Sugiyama,et al.  Predictive Value of Optimal Morphologic Response to First-Line Chemotherapy in Patients with Colorectal Liver Metastases , 2014, Digestion.

[23]  R. Goldin,et al.  Outcomes of simultaneous resections for patients with synchronous colorectal liver metastases. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  M. Choti,et al.  Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases , 2013, Cancer.

[25]  J. Vauthey,et al.  In patients with colorectal liver metastases, can we still rely on number to define treatment and outcome? , 2013, Oncology.

[26]  L. Rubbia‐Brandt,et al.  Liver Resection for Colorectal Metastases after Chemotherapy: Impact of Chemotherapy-Related Liver Injuries, Pathological Tumor Response, and Micrometastases on Long-term Survival , 2013, Annals of surgery.

[27]  M. Buyse,et al.  Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Cresswell,et al.  Close collaboration between local and specialist multidisciplinary teams allows ‘fast‐tracking’ of patients with colorectal liver metastases , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[29]  Steven A. Curley,et al.  RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.

[30]  M. Gonen,et al.  Comparison Between Perioperative and Postoperative Chemotherapy After Potentially Curative Hepatic Resection for Metastatic Colorectal Cancer , 2013, Annals of Surgical Oncology.

[31]  V. Heinemann,et al.  Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan‐based randomized first‐line trial , 2013, Cancer science.

[32]  Yu Bai,et al.  Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): Simultaneous or delayed? , 2013, Hepatology.

[33]  S. Curley,et al.  Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy , 2013, Annals of surgery.

[34]  A. M. G. Vicente,et al.  Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET. , 2013 .

[35]  U. Mansmann,et al.  Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial , 2013, Acta oncologica.

[36]  A. Ba-Ssalamah,et al.  Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation , 2013, European Radiology.

[37]  L. Capussotti,et al.  Colorectal Cancer with Synchronous Resectable Liver Metastases: Monocentric Management in a Hepatobiliary Referral Center Improves Survival Outcomes , 2013, Annals of Surgical Oncology.

[38]  A. Luciani,et al.  Single-center multidisciplinary management of patients with colorectal cancer and resectable synchronous liver metastases improves outcomes. , 2013, Clinics and research in hepatology and gastroenterology.

[39]  A. Ruzzenente,et al.  Usefulness of Contrast-Enhanced Intraoperative Ultrasonography (CE-IOUS) in Patients with Colorectal Liver Metastases after Preoperative Chemotherapy , 2013, Journal of Gastrointestinal Surgery.

[40]  J. Shindoh,et al.  Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T. Gruenberger,et al.  KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab , 2012, The British journal of surgery.

[42]  E. Van Cutsem,et al.  The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. , 2012, The oncologist.

[43]  J. Shindoh,et al.  Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases , 2012, Annals of surgery.

[44]  G. Chang.  Challenge of primary tumor management in patients with stage IV colorectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  N. Petrelli,et al.  Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Vauthey,et al.  Effect of specialist decision‐making on treatment strategies for colorectal liver metastases , 2012, The British journal of surgery.

[47]  A. Sundin,et al.  The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  R. Parks,et al.  Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983) , 2012, Annals of surgery.

[49]  Masahiro Yoshida,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer , 2012, International Journal of Clinical Oncology.

[50]  K. Hirakawa,et al.  A Meta-Analysis of the Short- And Long-Term Results of Randomized Controlled Trials That Compared Laparoscopy-Assisted and Open Colectomy for Colon Cancer , 2012, Journal of Cancer.

[51]  J. Vauthey,et al.  CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. , 2011, AJR. American journal of roentgenology.

[52]  S. Curley,et al.  Is resection of colorectal liver metastases after a second‐line chemotherapy regimen justified? , 2011, Cancer.

[53]  J. Ledermann,et al.  Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  T. Gruenberger,et al.  Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? , 2011, European journal of radiology.

[55]  C. Bokemeyer,et al.  Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Choti,et al.  Detection of Tumor DNA at the Margins of Colorectal Cancer Liver Metastasis , 2011, Clinical Cancer Research.

[57]  S. Curley,et al.  High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  E. Van Cutsem,et al.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M. Mottolese,et al.  Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial , 2010, British Journal of Cancer.

[60]  J. Vauthey,et al.  The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. , 2010, Clinical colorectal cancer.

[61]  E. Abdalla,et al.  Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases , 2010, The American journal of surgical pathology.

[62]  I. Nagtegaal,et al.  Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases , 2010, British Journal of Cancer.

[63]  S. Curley,et al.  Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? , 2010, Journal of the American College of Surgeons.

[64]  R. J. Haas,et al.  Liver resection of colorectal metastases in elderly patients , 2010, The British journal of surgery.

[65]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[66]  D. Sargent,et al.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  N. Kemeny,et al.  Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. Ychou,et al.  Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  Shenhong Wu,et al.  Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. , 2009, The Lancet. Oncology.

[70]  D. Vriens,et al.  Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review , 2009, Journal of Nuclear Medicine.

[71]  U. Motosugi,et al.  Imaging of Small Hepatic Metastases of Colorectal Carcinoma: How to Use Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging in the Multidetector-Row Computed Tomography Age? , 2009, Journal of computer assisted tomography.

[72]  W. Fawcett,et al.  A 10-year study of outcome following hepatic resection for colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[73]  L. Ellis,et al.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  R. Adam,et al.  R1 Resection by Necessity for Colorectal Liver Metastases: Is It Still a Contraindication to Surgery? , 2008, Annals of surgery.

[75]  K. Hatakeyama,et al.  Appraisal of 1 cm Hepatectomy Margins for Intrahepatic Micrometastases in Patients with Colorectal Carcinoma Liver Metastasis , 2008, Annals of Surgical Oncology.

[76]  T. de Baère,et al.  Percutaneous transhepatic portal vein embolization: rationale, technique, and outcomes. , 2008, Seminars in interventional radiology.

[77]  F. Lévi,et al.  Résection hépatique après traitement par agents ciblés de métastases hépatiques initialement non résécables n’ayant pas répondu à une chimiothérapie conventionnelle , 2008 .

[78]  L. Ellis,et al.  Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases , 2007, Cancer.

[79]  A. Neugut,et al.  Predictors of survival after hepatic resection among patients with colorectal liver metastasis , 2007, British Journal of Cancer.

[80]  M. Ducreux,et al.  Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  A. Carrato,et al.  Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. , 2007, European journal of cancer.

[82]  M. Choti,et al.  Simultaneous Resections of Colorectal Cancer and Synchronous Liver Metastases: A Multi-institutional Analysis , 2007, Annals of Surgical Oncology.

[83]  G. Cooper,et al.  Survival after hepatic resection in metastatic colorectal cancer , 2007, Cancer.

[84]  Francesco Leo,et al.  Multidisciplinary Management of Lung Cancer: How to Test Its Efficacy? , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[85]  L. Rubbia‐Brandt,et al.  Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  C. Lepage,et al.  Epidemiology and Management of Liver Metastases From Colorectal Cancer , 2006, Annals of surgery.

[87]  P. Morel,et al.  Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary , 2006, The British journal of surgery.

[88]  T. Pawlik,et al.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  O. Garden,et al.  Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies , 2006, British Journal of Cancer.

[90]  C Metcalfe,et al.  Analysis of clinical decision-making in multi-disciplinary cancer teams. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[91]  W. R. Sharp,et al.  A Steering and Visualization Toolkit for Distributed Applications , 2006, PDPTA.

[92]  B. Nordlinger,et al.  Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases , 2006, Annals of surgery.

[93]  M. Solomon,et al.  Meta‐analysis of short‐term outcomes after laparoscopic resection for colorectal cancer , 2004, The British journal of surgery.

[94]  Y. Panis,et al.  Detection of hypovascular hepatic metastases at triple-phase helical CT: sensitivity of phases and comparison with surgical and histopathologic findings. , 2004, Radiology.

[95]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  M. Ebell,et al.  Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. , 2004, The Journal of the American Board of Family Practice.

[97]  Yoshihiro Sakamoto,et al.  Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. , 2002, Archives of surgery.

[98]  K. Hatakeyama,et al.  Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases , 2002, Cancer.

[99]  H. Bismuth,et al.  Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors , 2000, Annals of surgery.

[100]  R. Barth,et al.  Interval hepatic resection of colorectal metastases improves patient selection. , 2000, Archives of surgery.

[101]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[102]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[103]  M. Borner.  Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  J. Crisp,et al.  The Delphi method? , 1997, Nursing research.

[105]  Murray Turoff,et al.  The Delphi Method: Techniques and Applications , 1976 .

[106]  N. Karanjia,et al.  Chemotherapy before liver resection of colorectal metastases: friend or foe? , 2015, Annals of surgery.

[107]  A. Scott,et al.  Metabolic Response to Preoperative Chemotherapy Predicts Prognosis for Patients Undergoing Surgical Resection of Colorectal Cancer Metastatic to the Liver , 2014, Annals of Surgical Oncology.

[108]  Mrcsi Cillian Clancy MB BCh,et al.  A Meta-Analysis to Determine the Effect of Primary Tumor Resection for Stage IV Colorectal Cancer with Unresectable Metastases on Patient Survival , 2014, Annals of Surgical Oncology.

[109]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[110]  A. Carrato,et al.  The rise and fall of a longed for clinical trial in patients with generalized colorectal cancer , 2013 .

[111]  K. Hatakeyama,et al.  Histologic evaluation of intrahepatic micrometastases in patients treated with or without neoadjuvant chemotherapy for colorectal carcinoma liver metastasis. , 2012, International journal of clinical and experimental pathology.

[112]  D. Shen,et al.  Impact of multidisciplinary team working on the management of colorectal cancer. , 2012, Chinese medical journal.

[113]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[114]  J. Figueras,et al.  Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. , 2001, Radiology.

[115]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.